Truist Bullish on ArriVent: $45 Target on Firmonertinib’s Lung Cancer Potential
Truist is bullish on ArriVent, rating Buy and seeing firmonertinib as a strong lung cancer drug with up to $1.1B peak sales.
/ 2 items
Truist is bullish on ArriVent, rating Buy and seeing firmonertinib as a strong lung cancer drug with up to $1.1B peak sales.
Cantor Fitzgerald initiates coverage on ArriVent Biopharma with an Overweight rating, highlighting strong Phase 3 potential and significant upside.